In Compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, Glaxosmithkline Pharmaceuticals has enclosed a copy of the Certificate received from Kfin Technologies, the Registrar and share Transfer Agent of the Company, for the quarter ended 31st March 2024.
The above information is a part of company’s filings submitted to BSE.